Morgan Stanley Has Lowered Expectations for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective decreased by investment analysts at Morgan Stanley from $300.00 to $240.00 in a report issued on Friday, Benzinga reports. The brokerage currently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley‘s price target would suggest a potential upside of 43.17% from the company’s current price.

Several other research analysts have also recently weighed in on the company. Chardan Capital restated a “buy” rating and issued a $425.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, July 31st. Wall Street Zen cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Wells Fargo & Company reduced their price objective on Alnylam Pharmaceuticals from $253.00 to $220.00 and set an “equal weight” rating for the company in a report on Friday. Zacks Research lowered Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 23rd. Finally, Oppenheimer dropped their price target on shares of Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $325.50.

Alnylam Pharmaceuticals Stock Down 3.7%

NASDAQ:ALNY traded down $6.36 on Friday, reaching $167.64. 3,318,160 shares of the stock traded hands, compared to its average volume of 1,501,652. The company has a market capitalization of $22.43 billion, a price-to-earnings ratio of 31.19 and a beta of 0.28. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75. The company’s fifty day simple moving average is $237.78 and its 200 day simple moving average is $287.22. Alnylam Pharmaceuticals has a 12 month low of $167.16 and a 12 month high of $479.79.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share for the quarter, topping analysts’ consensus estimates of $1.66 by $14.60. The company had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period in the previous year, the business earned $2.90 EPS. Equities analysts predict that Alnylam Pharmaceuticals will post 6.43 EPS for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, EVP Bryan Supran sold 1,758 shares of the business’s stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the transaction, the executive vice president owned 12,807 shares of the company’s stock, valued at approximately $2,905,652.16. The trade was a 12.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 0.86% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Legal & General Group Plc bought a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $278,321,000. Bank of New York Mellon Corp purchased a new position in shares of Alnylam Pharmaceuticals in the second quarter valued at $148,128,000. Canada Pension Plan Investment Board bought a new stake in Alnylam Pharmaceuticals in the second quarter worth $100,618,000. Korea Investment CORP bought a new stake in Alnylam Pharmaceuticals in the second quarter worth $74,553,000. Finally, Wellington Management Group LLP raised its position in shares of Alnylam Pharmaceuticals by 9.0% during the 2nd quarter. Wellington Management Group LLP now owns 2,110,407 shares of the biopharmaceutical company’s stock valued at $635,296,000 after buying an additional 174,482 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

More Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Q3 results exceeded expectations. Alnylam reported $16.26 in adjusted earnings per share versus the $1.66 consensus estimate, while revenue rose 16.7% year over year to $1.46 billion, ahead of estimates. The company maintained its fiscal 2026 net product-sales outlook. Alnylam Q3 earnings and revenue results
• Positive Sentiment: Long-term pipeline prospects remain supportive. Alnylam expects $4.2 billion-$4.5 billion in 2026 TTR sales and expanded the TRITON-CM nucresiran heart-disease study to approximately 2,250 patients while maintaining an expected launch timeline around 2030. Alnylam TTR sales and TRITON-CM update
• Neutral Sentiment: Analysts remain divided. Wells Fargo lowered its target to $220 and kept an “equal weight” rating; RBC cut its target to $280 but retained “outperform”; and Needham reduced its target to $243 while maintaining “buy.” These targets still imply substantial potential upside from recent levels.
• Negative Sentiment: Demand growth is the immediate concern. Slower U.S. Amvuttra patient starts and moderating Amvuttra and Onpattro sales growth raised questions about the pace of commercial expansion despite the quarterly beat. Alnylam demand growth concerns
• Negative Sentiment: Broker sentiment weakened. Bernstein downgraded Alnylam to “market perform” with a $199 target, while Stifel cut its rating to “hold” and set a $225 target. The reductions reflect greater caution around near-term growth and valuation.
• Negative Sentiment: Additional risk overhangs remain. An investor law firm announced an investigation related to a prior company disclosure, potentially adding to market uncertainty, although no wrongdoing has been established. Alnylam investor investigation

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.